Nootropil Dosage/Direction for Use





Full Prescribing Info
Dosage/Direction for Use
Symptomatic Treatment of Psycho-Organic Syndromes: The recommended daily dose ranges from 2.4 g up to 4.8 g, in two or three subdoses.
Treatment of Myoclonus of Cortical Origin: The daily dosage should begin at 7.2 g, increasing by 4.8 g every 3 or 4 days up to a maximum of 24 g, in two or three subdoses. Treatment with other antimyoclonic medicinal products should be maintained at the same dosage. Depending on the clinical benefit obtained, the dosage of the other such medicinal products should be reduced, if possible. Once started, treatment with piracetam should be continued for as long as the original cerebral disease persists.
In patients with an acute episode, spontaneous evolution may occur over time and an attempt should be made every 6 months to decrease or discontinue the medicinal treatment. This should be done by reducing the dose of piracetam by 1.2 g every 2 days (every 3 or 4 days in the case of a Lance and Adams syndrome, in order to prevent the possibility of sudden relapse or withdrawal seizures).
Treatment of Vertigo: The recommended daily dose ranges from 2.4-4.8 g in two or three subdoses.
Treatment of Dyslexia in Combination with Speech Therapy: Adolescents and Children from 8 years: The recommended daily dose is about 3.2 g, in two subdoses.
Elderly: Adjustment of the dose is recommended in elderly patients with compromised renal function (see Table 1). For long-term treatment in the elderly, regular evaluation of the CrCl is required to allow dosage adaptation if needed.
Renal Impairment: The daily dose must be individualized according to renal function. Refer to the following table and adjust the dose as indicated. To use this dosing table, an estimate of the patient's CrCl in mL/min is needed. The CrCl in mL/min may be estimated from the serum creatinine (mg/dL) determination using the following formula:

Click on icon to see table/diagram/image

Click on icon to see table/diagram/image

Hepatic Impairment: No dose adjustment is needed in patients with solely hepatic impairment. In patients with hepatic and renal impairment, adjustment dose is recommended (see Table 1).
Administration: Oral Formulations: Piracetam (Nootropil) may be taken with or without food. The film-coated tablet should be swallowed with liquid.
Route of Administration: Oral Formulations: For oral use.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in